Start Date
July 31, 2016
Primary Completion Date
June 30, 2019
Study Completion Date
June 30, 2019
OLAPARIB
Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
PLACEBO
Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
Research Site, Mobile
Research Site, Phoenix
Research Site, Los Angeles
Research Site, Stanford
Research Site, Augusta
Research Site, Park Ridge
Research Site, Iowa City
Research Site, Louisville
Research Site, Covington
Research Site, Scarborough
Research Site, Baltimore
Research Site, Albany
Research Site, Oklahoma City
Research Site, Philadelphia
Research Site, Milwaukee
Research Site, Chiclayo
Research Site, Lima
Research Site, Quezon City
Research Site, Goyang-si
Research Site, Seongnam-si
Research Site, Seoul
Research Site, Birmingham
Research Site, Cambridge
Research Site, Coventry
Research Site, Edinburgh
Research Site, London
Research Site, Manchester
Research Site, Oxford
Research Site, Sutton
Lead Sponsor
Myriad Genetic Laboratories, Inc.
INDUSTRY
AstraZeneca
INDUSTRY